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Abstract
Background: During inflammation, adhesion molecules regulate recruitment of leukocytes to inflamed tissues. It is reported
that vascular cell adhesion molecule-1 (VCAM-1) activates extracellular regulated kinases 1 and 2 (ERK1/2), but the
mechanism for this activation is not known. Pharmacological inhibitors of ERK1/2 partially inhibit leukocyte transendothelial
migration in a multi-receptor system but it is not known whether VCAM-1 activation of ERK1/2 is required for leukocyte
transendothelial migration (TEM) on VCAM-1.
Methodology/Principal Findings: In this study, we identified a mechanism for VCAM-1 activation of ERK1/2 in human and
mouse endothelial cells. VCAM-1 signaling, which occurs through endothelial cell NADPH oxidase, protein kinase Ca (PKCa),
and protein tyrosine phosphatase 1B (PTP1B), activates endothelial cell ERK1/2. Inhibition of these signals blocked VCAM-1
activation of ERK1/2, indicating that ERK1/2 is activated downstream of PTP1B during VCAM-1 signaling. Furthermore,
VCAM-1-specific leukocyte migration under physiological laminar flow of 2 dynes/cm
2 was blocked by pretreatment of
endothelial cells with dominant-negative ERK2 K52R or the MEK/ERK inhibitors, PD98059 and U0126, indicating for the first
time that ERK regulates VCAM-1-dependent leukocyte transendothelial migration.
Conclusions/Significance: VCAM-1 activation of endothelial cell NADPH oxidase/PKCa/PTP1B induces transient ERK1/2
activation that is necessary for VCAM-1-dependent leukocyte TEM.
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Introduction
The transendothelial migration (TEM) of leukocytes is critical
for inflammatory responses, immune surveillance, leukocyte
homing and mobilization of hematopoietic progenitor cells [1].
The process of TEM involves the sequential rolling and firm
adhesion of leukocytes on vascular adhesion molecules followed by
the diapedesis of the bound leukocytes [1]. The vascular adhesion
molecule VCAM-1 mediates leukocyte rolling and adhesion to
endothelium during VCAM-1-dependent eosinophil infiltration
into the lung in experimental ovalbumin-induced asthma [2], as
well as T-cell infiltration across the blood-brain barrier in
experimental allergic encephalomyelitis [3]. VCAM-1-dependent
migration is important in vivo because, in several diseases,
leukocytes migrate on VCAM-1[4]. Because of this critical role
for VCAM-1 in these diseases, targeting of VCAM-1 or its ligand
VLA-4 has been used to treat clinical disease [4].
Leukocyte binding to vascular cell adhesion molecule-1
(VCAM-1) triggers signaling events in endothelial cells that are
critical during VCAM-1-dependent TEM. We have previously
reported that VCAM-1 activates the endothelial cell NADPH
oxidase NOX2, which catalyzes the release of low levels of reactive
oxygen species (ROS) (1 mMH 2O2) [5,6]. H2O2 diffuses through
membranes to oxidize and transiently activate endothelial cell-
associated protein kinase Ca (PKCa) [7,8]. PKCa then phos-
phorylates and activates endothelial cell protein tyrosine phospha-
tase 1B (PTP1B) [7,8]. VCAM-1 signals through ROS, PKCa,
and PTP1B are required for VCAM-1-dependent leukocyte TEM
in vitro [4,5,6,7,8]. It has been reported that NOX2 and ROS are
required for VCAM-1-dependent leukocyte recruitment in vivo
[4,9,10,11].
It has also been reported that VCAM-1 ligation activates the
serine/threonine kinases extracellular regulated kinases 1 and 2
(ERK1/2) [12] but the mechanism for this activation is not known.
It is reported that in cytokine-stimulated primary cultures of
endothelial cells, inhibition of ERK1/2 with pharmacological
inhibitors, which have additional off-target effects, partially
inhibits leukocyte transendothelial migration across the endothelial
cells in vitro [12,13]. Moreover, because the cytokine-stimulated
primary endothelial cells express several adhesion molecules that
support leukocyte transendothelial migration, it is not known in
these studies whether ERK1/2 is involved in VCAM-1-mediated
leukocyte transendothelial migration.
In this report, we demonstrate, in primary cultures of human
endothelial cells and mouse endothelial cell lines, that VCAM-1
activation of endothelial cell ERK1/2 is mediated by endothelial
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endothelial ERK2 blocks VCAM-1-dependent leukocyte transen-
dothelial migration.
Results
Endothelial cell ERK1/2 is required for VCAM-1-
dependent leukocyte migration across endothelial cells
It is reported that pharmacological inhibition of ERK1/2 with
PD98059 blocks leukocyte transendothelial migration across
endothelial cells that express multiple adhesion molecules [12].
However, it is not known whether VCAM-1-mediated leukocyte
transendothelial migration requires ERK1/2 or ERK’s classical
upstream activator MEK1/2. Therefore, we determined whether
endothelial MEK1/2 and ERK2 are required for VCAM-1-
dependent leukocyte migration. We used pharmacological inhibi-
torsanddominant negativeERK1/2 approaches toblockMEK1/2
or ERK1/2. To examine the function of VCAM-1 signals during
VCAM-1-dependent leukocyte transendothelial migration, the
endothelial cell line mHEVa was used because it expresses
VCAM-1 but not other known adhesion molecules for leukocyte
transendothelial migration [4]. It is previously reported that this
migration assay is dependent on the constitutively expressed
VCAM-1. Blocking with anti-VCAM-1 or anti-VLA4 antibodies
immediatelybeforethe additionofleukocytestothe endothelialcells
inhibits leukocyteadhesion and migration[4,6,14,15]. The VCAM-
1-mediated transendothelial migration is also dependent on
VCAM-1 signal transduction through NOX2, PKCa, PTP1B,
and matrix metalloproteinases and on endothelial cell production of
the chemokine MCP-1 [4,5,6,7,8,14,16]. Moreover, antibody
crosslinking of VCAM-1 activates these VCAM-1 signals with the
same magnitude and time course in the mHEVa cell lines as in
primary cultures of endothelial cells [4,5,7,8,16].
To examine endothelial MEK1/2 function in VCAM-1-
dependent TEM, confluent monolayers of mHEVa cells were
nontreated or pretreated for 30 minutes with two inhibitors of
MEK1/2, PD98059 or U0126. PD98059 was chosen since reports
show that it inhibits activation of inactive MEK1 and MEK 2 with
IC50 values of 4 mM and 50 mM, respectively [17,18,19]. U0126
irreversibly inhibits both active and inactive MEK1/2 [19].
U0126 has been found to be a selective and highly potent selective
inhibitor of MAPK cascade with IC50 values of 70 and 60 nM for
purified MEK1 and MEK2, respectively [19,20]. The endothelial
cells were pretreated with MEK inhibitors PD98059 (20 mM) or
U0126 (10–40 mM) at doses typically used (50 mM) for inhibition
of this enzyme in endothelial cells [21,22]. After treatment with
these MEK1/2 inhibitors, the endothelial cells were washed five
times. The last wash was added to a set of untreated endothelial
cells to demonstrate that effective concentrations of free inhibitor
were removed since there was no effect of the last wash on TEM
(data not shown). Spleen leukocytes which were .90% lympho-
cytes were added. After 15 minutes at 2 dynes/cm
2 laminar flow,
the monolayers were washed and fixed; leukocyte transendothelial
migration was quantified by phase contrast microscopy [23]. Anti-
VCAM-1 blocking antibodies inhibited leukocyte transendothelial
migration and leukocyte adhesion (Figure 1A–D) but migration
was not blocked by isotype control antibodies as we previously
reported [5]. The MEK inhibitors did not affect cell viability as
determined by trypan blue exclusion (data not shown), did not
increase relative cytotoxicity as compared to the nontreated
control as determined by the G6PDH release assay (Figure 1E)
and did not affect the expression of VCAM-1 as determined by
flow cytometry (data not shown). PD98059 (20 mM) and U0126
(30–40 mM) significantly inhibited leukocyte transmigration
(Figure 1A,B). Furthermore, neither PD98059 nor U0126
inhibited leukocyte adhesion (Figure 1C,D), indicating that
endothelial cell MEK1/2 is not required for leukocyte adhesion
but is required for the leukocyte TEM.
It was also determined whether transient transfection of
mHEVa cells with the ERK2 dominant negative GFP-ERK2
K52R [24] blocks VCAM-1-dependent leukocyte TEM. The cells
expressed the dominant negative ERK2 K52R as examined by
western blot (Figure 2A). Under our optimized conditions for
transfection as described in the methods, GFP-ERK2 K52R-
Figure 1. Inhibition of MEK, which is known to activate ERK1/2,
blocks VCAM-1-dependent spleen leukocyte TEM. Confluent
monolayers of mHEVa cells were nontreated (NT) or treated for 30
minutes with the MEK inhibitors PD98059 (20 mM) or U0126 (20–
40 mM). To block leukocyte binding to VCAM-1, the endothelial cells
were treated with a blocking anti-VCAM-1 antibody without a
secondary crosslinking antibody. A–D) Splenic leukocytes were added
to the endothelial monolayer, allowed to briefly settle to mediate cell
contact and then exposed to 2 dynes/cm
2 laminar flow for 15 minutes
to examine migration (A and B) or 2 minutes to examine leukocyte-
endothelial cell association (C and D). Then, cells were washed and
fixed in 3% paraformaldehyde for 1 hour and examined by phase
contrast microscopy [7,8,65]. Non-migrated leukocytes are phase-light
and migrated leukocytes appear as phase-dark [7,8,65]. We previously
reported that the leukocytes that migrated are .88% lymphocytes as
determined by flow cytometry [6]. E) Relative cytotoxicity was
determined by the G6PDH assay; PD98059 (20 mM) and U0126
(40 mM) were not cytotoxic as compared to the nontreated control
cells. Data in each panel are from 3 experiments. *, p,0.05 compared to
A,C) NT groups, B,D) 0 minutes groups, or compared to DMSO-treated
or last washes (data not shown). Inhibitors had no effect on cell viability,
as determined by Trypan blue exclusion (data not shown).
doi:10.1371/journal.pone.0026706.g001
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cultured in chamber slides for 4 hours had .70% transfection
efficiency as analyzed by flow cytometry for GFP (Figure 2B).
The transfection did not affect mHEVa cell expression of VCAM-
1 as determined by immunolabeling and flow cytometry (data not
shown). The transfected endothelial cells were plated at a density
to form confluent monolayers in 4 hours. The endothelial cells
were greater than 85% viable at 4 hours of culture (data not
shown). In contrast, since ERK1/2 is a survival signal for
endothelial cells [25,26,27,28,29,30], at 24 hours of culture the
dominant negative ERK1/2 transfected cells began to undergo
cell death whereas vector transfected cells survive (data not
shown). Therefore, the transient transfection studies were
performed at 4 hours when confluent monolayers of viable
endothelial cells are formed. At 4 hours post transfection, TEM
studies were performed in the parallel plate flow chamber assay at
2 dynes/cm
2 laminar flow or static conditions for 15 minutes [8].
The transfection with the dominant negative ERK2 K52R
inhibited VCAM-1-dependent leukocyte TEM as compared to
the vector control under laminar flow (Figure 2C) or static
conditions (data not shown). Anti-VCAM-1 blocking antibodies
inhibited leukocyte transendothelial migration for all the treat-
ments compared to the vector-treated group without anti-VCAM-
1( Figure 2C). The dominant negative ERK2 K52R did not alter
the number of leukocytes associated with the endothelial cells as
compared to the vector-transfected cells under laminar flow
conditions (Figure 2D) or static conditions (data not shown).
Anti-VCAM-1 blocking antibodies inhibited leukocyte association
with the endothelial cells for all the treatments compared to the
corresponding groups without anti-VCAM-1 (Figure 2D).I n
summary, it is demonstrated for the first time that ERK2 activity is
necessary for VCAM-1-dependent leukocyte TEM.
VCAM-1 activates ERK1/2 downstream of NADPH
oxidase, PKCa, and PTP1B in mouse endothelial cell lines
that mediate VCAM-1-dependent leukocyte
transendothelial migration
Endothelial cell signals are required for VCAM-1-dependent
leukocyte transendothelial migration [4]. We have reported that,
during transendothelial migration, VCAM-1 activates NADPH
oxidase for the generation of superoxide and its metabolite H2O2;
the ROS oxidize and activate PKCa that then activates PTP1B
[4]. Therefore, we examined anti-VCAM-1 activation of ERK1/2
under static and laminar flow conditions and then determined
whether the ERK1/2 activation is blocked by inhibitors of
NADPH oxidase, PKCa, or PTP1B.
To examine the time course for anti-VCAM-1 activation of
ERK1/2 under static and laminar flow conditions, confluent
monolayers of mHEVa cells were stimulated with a confluent
monolayer of anti-VCAM-1 antibody-coated beads for 10 to
60 min. Antibody crosslinking of VCAM-1 mimics physical
leukocyte interaction with endothelial cells for the activation of
VCAM-1-dependent signals [5,6,7,8,16]. The negative control
included treatment with a confluent monolayer of anti-CD98
antibody-coated beads for 10 to 60 min, since CD98 is expressed
by mHEVa cells, but does not signal through ERK1/2 [31]. After
stimulation with antibody-coated beads, the cells were examined
by Western blot for phosphorylation of ERK1/2 Thr202/Tyr204,
the active form of ERK1/2. Antibody crosslinking of VCAM-1
under static conditions induced an increase in ERK1/2 phos-
phorylation at 15–30 minutes in mHEVa cells (Figure 3A).
VCAM-1 stimulation did not increase total ERK1/2 expre-
ssion (Figure 3A–B). There was no increase in ERK1/2
Figure 2. Inhibition of endothelial cell ERK1/2 with an ERK2
dominant negative plasmid (K52R) blocks VCAM-1-dependent
leukocyte migration. Two million mHEVa endothelial cells, that were
grown to 70,80% confluence, were suspended with trypsin and
transfected with GFP-ERK2 K52R or vector control using the Amaxa
nucleofector method. Transfected cells were seeded onto 9 cm
2 culture
slides. Four hours after nucleofection, cells were examined for ERK1/2
expression or used in TEM assays. Greater than 60% of the endothelial
cells were transfected as determined by flow cytometry with detection
of GFP-ERK2 K52R (data not shown). The transfected endothelial cells
formed confluent monolayers in 4 hours and were greater than 85%
viable (data not shown). In addition, to block leukocyte binding to
VCAM-1, the endothelial cells were treated with a blocking anti-VCAM-1
antibody without a secondary crosslinking antibody. A) The endothelial
cells were washed with ice-cold phosphate-buffered saline and
examined by western blot for ERK1/2 and b-actin expression. Lanes 1
and 2 are two samples of vector-treated cells. Lanes 3 and 4 are two
samples of cells treated with GFP-ERK2 K52R. B) Leukocyte TEM under
laminar flow at 2 dynes/cm
2, C) Leukocyte association assay under
laminar flow at 2 dynes/cm
2. Data for each panel are from 3
experiments. *, p,0.05 compared to non-treated (NT) or vector
transfected groups.
doi:10.1371/journal.pone.0026706.g002
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(Figure 3B). To study the effect of laminar flow on ERK1/2
activation, confluent monolayers of endothelial cells were
assembled in parallel plate flow chambers, anti-VCAM-1-coated
beads or anti-CD98-coated beads were added to the flow chamber
and then laminar flow at 2 dynes/cm
2 was applied for 15 minutes.
Equivalent numbers of the anti-VCAM-1-coated beads or anti-
CD98-coated beads were loaded onto the endothelial cells and
were bound to the endothelial cells (data not shown). To avoid
stimulation of the endothelial cells by serum growth factors in fresh
culture medium, we perfused the laminar flow chambers with
media taken from cultured mHEVa cells. ERK1/2 Thr202/
Tyr204 phosphorylation was significantly increased when mHEVa
cells were stimulated with anti-VCAM-1 beads, compared to
nontreated or the anti-CD98 binding controls under flow
conditions (Figure 3C). When we compared nontreated
endothelial cells under static conditions with nontreated endothe-
lial cells under flow conditions, there was a significant but modest
increase in ERK1/2 Thr202/Tyr204 phosphorylation in non-
treated cells under laminar flow (Figure 3C), consistent with
previous reports that laminar flow induces some ERK1/2
activation [32,33]. Anti-VCAM-1 under flow induced a greater
increase in ERK1/2 phosphorylation compared to stimulation
under static conditions (5 fold increase under flow versus 3 K fold
increase under static conditions) (Figure 3). Together, these data
suggest that VCAM-1 stimulates an increase in endothelial
ERK1/2 activity under both static and laminar flow at 2 dynes/
cm
2.
Then, we determined whether ERK1/2 is activated by VCAM-
19s signaling cascade (NADPH oxidase, 1 mMH 2O2, PKCa and
PTP1B). Anti-VCAM-1 activation of ERK1/2 Thr202/Tyr204
phosphorylation in mHEVa cells under static conditions was
blocked by the NADPH oxidase inhibitor apocynin or scavenging
extracellular ROS with catalase (Figure 4A, C), suggesting that
ERK1/2 functions downstream of NADPH oxidase. In the
absence of VCAM-1 stimulation, apocynin and catalase did not
alter background ERK1/2 phosphorylation (data not shown).
Since we previously reported that binding to VCAM-1 stimulates
endothelial cell NADPH oxidase, resulting in the generation of
1 mMH 2O2 [5] and that exogenous addition of 1 mMH 2O2 is
sufficient for the activation of PKCa and PTP1B in endothelial
cells at 10 minutes [7,8], it was determined whether exogenous
1 mMH 2O2 activated endothelial cell ERK1/2. At 10 minutes,
1 mMH 2O2 significantly increased ERK1/2 Thr202/Tyr204
phosphorylation in mHEVa cells (Figure 4D). Therefore,
exogenous ROS, at concentrations that are generated by
VCAM-1-outside-in signals [6], stimulate a significant increase
in ERK1/2 phosphorylation. Anti-VCAM-1 activation of ERK1/
2 Thr202/Tyr204 phosphorylation in mHEVa cells was also
blocked by the PKCa inhibitor Go ¨-6976, and the PTP1B inhibitor
CinnGEL 2-methyl ester (Figure 4B). At these concentrations,
none of the inhibitors had any significant effects on the basal level
of ERK1/2 in the absence of anti-VCAM-1 stimulation (data not
shown). The inhibitors used at these optimal doses did not affect
cell viability as we previously reported [7,8].
Since ERK1 and ERK2 are classically activated through MEK1
and MEK2-mediated phosphorylation of ERK’s activation loop
residues Thr202/Tyr204 on ERK1 and Thr185/Tyr187 on
ERK2 [34], we determined whether MEK1/2 mediated VCAM-1
activation of ERK1/2. In confluent monolayers of mHEVa cells,
antibody crosslinking of VCAM-1 significantly increased serine
217/221 phosphorylation of MEK1/2 at 15 to 30 minutes as
compared to nontreated cells (Figure 4E); this time course is
similar to the 15–30 minutes for activation of ERK1/2 in
Figure 3A. The MEK1/2 inhibitor PD98059 blocked VCAM-1-
activated phosphorylation of ERK1/2 (Figure 4A) and leukocyte
transendothelial migration (Figure 1A,C). In contrast, inhibition
of MEK1/2 with PD98059 or U0126 did not block activation of
PKCa (Figure 4F), indicating that MEK1/2 and ERK1/2
function downstream of PKCa during VCAM-1 signaling.
Together, the data indicate that, during VCAM-1 signaling,
ERK1/2 functions downsteam of NADPH oxidase, PKCa, and
Figure 3. VCAM-1 induces an increase in phosphorylation of
ERK1/2 in endothelial cell lines under static and laminar flow
conditions. Confluent monolayers of mHEVa cells were stimulated
with 27 mg/ml anti-VCAM-1 (or the binding control anti-CD98) plus
15 mg/ml of a secondary antibody. ERK1/2 Thr202/Tyr204 phosphory-
lation (P-ERK1/2) and total ERK1/2 was determined by western blot. A)
Time course for anti-VCAM-1 activation of ERK1/2 Thr202/Tyr204
phosphorylation under static conditions. B) Stimulation of VCAM-1 for
30 minutes and time course for antibody crosslinking of the control
CD98 under static conditions. C) Confluent monolayers of HEV were
non-treated (NT) or stimulated with anti-VCAM-1 or the control anti-
CD98 under 2 dynes/cm
2 laminar flow or nontreated under static
conditions for 15 minutes. *, p,0.05 compared to A) 0 minutes, B)N T
and C) the NT,flow group. In panel C) **, p,0.5 compared to the anti-
VCAM-1, flow group.
doi:10.1371/journal.pone.0026706.g003
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PLoS ONE | www.plosone.org 4 October 2011 | Volume 6 | Issue 10 | e26706Figure 4. Mechanisms for VCAM-1 activation of ERK1/2 in endothelial cell lines. Monolayers of mHEVa cells were nontreated (NT) or
incubated for 30 minutes with apocynin (4 mM), PD98059 (30uM), U0126 (40 mM), Go ¨-6976 (2.3 nM), CinnGEL 2-methylester (10 mM), or catalase
(5000 U/ml) where indicated. These are the optimal doses for these inhibitors as we have previously described [5,7,8]. At these concentrations, none
of the inhibitors had any significant effects on the basal level of ERK1/2 in the absence of anti-VCAM-1 stimulation (data not shown). After treatement
with the inhibitor, the endothelial cells were stimulated with anti-VCAM-1 antibody plus a secondary antibody to crosslink VCAM-1 for 30 min under
static conditions. We examined phosphorylation of A,B,F) ERK1/2 Thr202/Tyr204 (P-ERK1/2), C) PKCa Thr638 (P-PKCa), or D) MEK1/2 Ser217/221 (P-
MEK1/2) by western blot. E) mHEVa cells were treated with exogenous 1 mMH 2O2 for 10–60 minutes and ERK1/2 Ser217/221 phosphorylation was
determined by western blot. The phosphorylation status of ERK1/2 Thr202/Tyr204, PKCa Thr638, or MEK1/2 Ser217/221 is presented as the fold
increase in the ratio of the relative intensity of the phosphorylated enzyme to total ERK1/2, total PKCa or total MEK1/2 expression. Representative
western blots are shown and data are presented as the mean 6 standard deviation from 3 experiments. (A, B)* ,p ,0.05 less than anti-VCAM-1-
treated group. (C–F)* ,p ,0.05 greater than NT.
doi:10.1371/journal.pone.0026706.g004
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dependent leukocyte transendothelial migration.
VCAM-1 activates ERK1/2 downstream of NADPH
oxidase, PKCa, and PTP1B in primary cultures of human
endothelial cells
We have reported that, in primary cultures of human
endothelial cells, VCAM-1 signals through NADPH oxidase,
PKCa and PTP1B [7,8]. Therefore, we determined whether
VCAM-1 activates ERK1/2 downstream of NADPH oxidase,
PKCa, and PTP1B in primary cultures of human microvascular
endothelial cells from the lung (HMVEC-L). For these studies,
HMVEC-Ls were treated overnight with 10 ng/ml TNFa to
induce expression of several adhesion molecules, including
VCAM-1 and ICAM-1 [7,8,35,36]. TNFa induced expression of
VCAM-1 by HMVEC-L cells as determined by immunolabeling
and fluorescence microscopy (data not shown). Therefore, since
TNFa induces expression of several adhesion molecules, VCAM-1
on TNFa-treated HMVEC-Ls was specifically activated by
crosslinking with anti-VCAM-1 plus a secondary antibody for 10
to 30 min and then analyzed by Western Blot for Thr202/Tyr204
phosphorylation of ERK1/2. Stimulation of VCAM-1 at 15
minutes induced Thr202/Tyr204 phosphorylation of ERK1/2 in
TNFa -pretreated cultures of HMVEC-L cells without altering
total ERK1/2 (Figure 5A, B). This time point for human
VCAM-1 activation of ERK1/2 in human endothelial cells is
generally consistent with the time course for mouse VCAM-1
activation of ERK1/2 in the murine endothelial cell lines, even
though the anti-human VCAM-1 and anti-mouse VCAM-1
antibodies differ. In addition, the time course for VCAM-1
activation of ERK1/2 in HMVEC-Ls is consistent with the time
course for VCAM-1 signaling in HMVEC-Ls including maximal
stimulation of PKCa at 10 minutes and PTP1B at 15 minutes
[7,8]. To determine whether ERK1/2 functions downstream of
NADPH oxidase, PKCa and PTP1B during VCAM-1 signaling,
TNF-a stimulated HMEVC-L cells were treated with the vehicle
control 0.1% DMSO, the NADPH oxidase inhibitor apocynin
(4 mM), the PKCa inhibitor Go ¨-6976 (2.3 nM) or the PTP1B
inhibitor CinnGEL 2-methylester (10 mM) for 30 min and then
stimulated with anti-VCAM-1 plus secondary antibody for
15 min. The inhibitors were used at the optimal doses and they
did not affect endothelial cell viability as we previously reported
[5,7,8]. None of the inhibitors had any significant effects on the
basal level of ERK1/2 protein expression in the absence of anti-
VCAM-1 as determined by western blot (data not shown). Anti-
VCAM-1-activated Thr202/Tyr204 phosphorylation of ERK1/2
was blocked by inhibitors of NADPH oxidase, PTP1B and PKCa
(Figure 5B). Together, these data indicate that VCAM-1
activates ERK1/2 downstream of NADPH oxidase, PKCa and
PTP1B in mouse endothelial cell lines (mHEVa cells) and primary
cultures of endothelial cells (HMVEC-L cells). This is the first
report for a mechanism for VCAM-1 activation of ERK1/2.
Discussion
In this manuscript, we report that VCAM-1 activation of
ERK1/2 participates in VCAM-1-dependent leukocyte transen-
dothelial migration and identify a mechanism for VCAM-1
activation of ERK1/2 in endothelial cells. VCAM-1-activated
ERK2 activity is necessary for VCAM-1-dependent leukocyte
migration across mHEVa cells, because migration is inhibited by
anti-VCAM-1 blocking antibodies [5,6], by the ERK1/2 inhib-
itors PD98059 or U0126, and by transient transfection of
endothelial cells with the dominant negative ERK2 K52R.
Furthermore, endothelial ERK1/2 functions downstream of
VCAM-1-activated NADPH oxidase, because the inhibitor
apocynin blocked anti-VCAM-1-dependent ERK1/2 activation
and we have previously reported that VCAM-1 does not signal
through other ROS-generating enzymes [4]. ROS were sufficient
for activation of ERK1/2 since exogenous addition of 1 mM
H2O2, which corresponds to the level of H2O2 produced during
VCAM-1 signaling [6,15], increased ERK1/2 activation with
about the same magnitude and time course as anti-VCAM-1.
Moreover, we report that ERK1/2 activation was dependent on
VCAM-1-activated PKCa [8] and PTP1B [7] in human primary
Figure 5. Mechanisms for VCAM-1 activation of ERK1/2 in
HMVEC-L. Treatment of HMVEC-L cells overnight with 10ng/ml TNF-a
induced VCAM-1 expression (data not shown). A) Confluent monolayers
of TNF-a-treated HMVEC-Ls were nontreated (NT) or treated with 27 mg/
ml anti-VCAM-1 plus 15 mg/ml of a secondary antibody to crosslink and
stimulate VCAM-1. Phosphorylation of ERK1/2 Thr202/Tyr204 (P-ERK1/2)
and total expression of ERK1/2 was examined by western blot using
rabbit anti-phospho ERK1/2 Thr202/Tyr204 (1/1000) followed by HRP-
conjugated anti-rabbit (1/2000) and ECL detection. B)C o n f l u e n t
monolayers of TNF-a stimulated HMVEC-L cells in 12 well plates were
nontreated or incubated for 30 minutes with the solvent control DMSO,
apocynin (4 mM), Go ¨-6976 (2.3 nM) or CinnGEL 2-methylester (10 mM).
These endothelial cells were then stimulated with anti-VCAM-1
antibody plus a secondary antibody for 15 minutes. The apocynin,
DMSO, Go ¨-6976 or CinnGEL 2-methylester had no effect on endothelial
cell viability as determined by trypan blue exclusion and had no effect
on VCAM-1 expression as determined by flow cytometry (data not
shown). Representative western blots are shown. Data presented are
the mean 6 standard deviation from 3 experiments. The phosphory-
lation status of ERK1/2 is presented as the fold increase in the ratio of
the relative intensity of P-ERK1/2 divided by the relative intensity of the
loading control (total ERK1/2). *, p,0.05 compared to A) NT cells or B)
anti-VCAM-1 stimulated cells.
doi:10.1371/journal.pone.0026706.g005
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inhibition of PKCa and PTP1B blocked VCAM-1 activation of
ERK1/2. Thus, VCAM-1 binding increased Thr202/Tyr204
phosphorylation of ERK1/2 in mouse endothelial cell lines and in
human primary cultures of endothelial cells and this activation was
downstream of VCAM-1 activation of NADPH oxidase, PKCa,o r
PTP1B. This is the first study that identifies a mechanism for
VCAM-1 activation of ERK1/2 during leukocyte TEM.
It has been reported that endothelial cell ERK1/2 functions in
leukocyte TEM since pretreatment of endothelial cells with a
MEK1/2 inhibitor, PD98059, attenuates eosinophil transmigra-
tion across primary cultures of HUVECs that express several
adhesion molecules [12,37]. Since several adhesion molecules
were expressed by the endothelial cells, it is not known in their
studies whether ERK1/2 was required for VCAM-1-mediated
leukocyte TEM. Moreover, this MEK1/2 inhibitor PD98059, has
been demonstrated to have off target effects of inhibition of
voltage-dependent Ca2+ channels [38] and we have reported that
VCAM-1 signals through Ca2+ channels [15]. Besides our
pharmacological approach demonstrating that two MEK inhibi-
tors U0126 and PD98059 block VCAM-1-dependent leukocyte
TEM, we report, using a molecular approach, that VCAM-1
activation of ERK1/2 is required for VCAM-1-dependent TEM
since transient transfection of endothelial cells with dominant
negative ERK2 K52R reduced leukocyte TEM on VCAM-1.
Thus, VCAM-1-activated ERK1/2 is an obligatory signal in
VCAM-1-dependent TEM.
It has been reported that VCAM-1 ligation in large vessel
endothelial cells (human umbilical vein endothelial cells, HU-
VECs) induces an increase in ERK2 activity [12] but they did not
report a mechanism for activation. They showed that VCAM-1
activated ERK2 under laminar flow but not static conditions [12].
In contrast, we demonstrate that anti-VCAM-1-coated beads
stimulate an increase in ERK1/2 phosphorylation under both
laminar flow or static conditions in mHEVa cells or HVMEC-L
cells without adding fresh media. In our studies, under the flow
conditions of 2 dynes/cm
2, ERK1/2 phosphorylation was ampli-
fied as compared to static conditions. It is possible that in the
previous report [12], they did not detect a VCAM-1-induced
activation of ERK2 under static conditions as a result of
differences in serum conditions, static/flow conditions, or
differences in endothelial cell sources (microvascular endothelial
cells versus large vessel HUVECs).
It has been reported that there is increased activity of MAPKs
with ligation of ICAM-1, VCAM-1 or E-selectin ligation in
epithelial [39,40,41] and endothelial cells [12,42,43,44,45].
Adherence of neutrophils or ICAM-1 crosslinking activates ERK
in endothelial cells [42,43,46,47,48], epithelial cells [39,40,49,50],
and smooth muscle cells [13]. Moreover, ligation of E-selectin
leads to shear-dependent ERK1/2 phosphorylation in HUVECs
[12,44]. Thus, several adhesion molecules activate ERK/12 in
different cell types. In this study, we report a mechanism for
VCAM-1 activation of ERK1/2 via activation of NADPH
oxidase, PKCa and PTP1B in microvascular mouse endothelial
cell lines and human microvascular endothelial cells. In contrast,
crosslinking of another endothelial cell surface molecule, CD98,
does not activate ERK1/2, indicating that VCAM-1 activation of
ERK is specific.
Others report that endothelial cell ERK1/2 or p38 MAPK
activation can occur downstream of intracellular oxidant gener-
ation [45,51,52,53]. For example, oxygen-derived free radicals
were previously reported to induce the activation of ERKs and
p38 MAPKs in cultured cardiac myocytes [54]. Receptors other
than VCAM-1 have been reported to activate ERK1/2 through
reactive oxygen species (ROS) in endothelial cells [51,52,53] or
PKC-dependent signaling pathways in epithelial cells and T cells
[41,50,55,56,57,58]. Whether there is crosstalk between these
adhesion molecules through PKCa and ERK1/2 is not known.
Regarding adhesion molecule signaling crosstalk, there may be
crosstalk since both VCAM-1 and ICAM-1 signal through
PKCa[4]. However, the adhesion molecule signaling pathways
differ since VCAM-1 signals through NADPH oxidase whereas
ICAM-1 signals through xanthine oxidase [4,59]. Moreover, the
adhesion molecule PECAM-1 does not signal through reactive
oxygen species [5]. Thus, there are unique signals for these
adhesion molecules as well as potential points for crosstalk between
some of the adhesion molecules. In this report, we demonstrate
that low levels of VCAM-1-stimulated ROS generation, which
activate PKCa and PTP1B, induced signals for phosphorylation of
ERK1/2 in mouse endothelial cells (mHEVa) and human
endothelial cells (HMVEC-Ls). This is consistent with our previous
studies demonstrating that pharmacological or molecular ap-
proaches to inhibit VCAM-1-induced signals through ROS,
PKCa and PTP1B block leukocyte TEM in vitro and block
VCAM-1-dependent leukocyte recruitment in vivo [4,5,7,8,16].
In summary, the data in this report demonstrate that ERK1/2
is a distal signaling intermediate in the VCAM-1-induced NADPH
oxidase/PKCa/PTP1B signal transduction pathway and that the
activation of ERK1/2 is required for VCAM-1-dependent
leukocyte TEM. Thus, VCAM-1 activates the following signaling
cascade to support TEM: VCAM-1 activates endothelial cell
NADPH oxidase to generate ROS [4,5]; these ROS transiently
activate PKCa [4,8]; PKCa activity then transiently activates
PTP1B [4,7]; the PTP1B activates signals that then induce an
increase in Thr202/Tyr204 phosphorylation of ERK1/2.
Materials and Methods
Cells
Human microvascular endothelial cells from the lung
(HMVEC-Ls) (CC-Lonza, Walkersville, MD) were grown in
EGM-MV endothelial growth medium plus 5% FCS (catalog
#CC-3125, Lonza) and were used at passage 2–6. The high
endothelial venule-like cell line mHEVa cells was previously
derived from BALB/c mouse axillary lymph nodes and cultured as
described [60]. The mHEVa cells have been spontaneously
immortalized but are not transformed and are constitutively
activated with expression of VCAM-1 and MCP-1 [60]. The
mHEV cells are an endothelial cell model for examining VCAM-1
function during transendothelial migration. For leukocytes, single
cell suspensions were obtained from spleens of male 6-8 week old
BALB/c mice (Jackson Laboratories) as previously described
4 and
the red blood cells were lysed by hypotonic shock [60]. Spleens are
used because they are an abundant source of leukocytes and the
spleen is contiguous with the blood. The animal procedures were
reviewed and approved by the Animal Care and Use Committee
at Northwestern University.
Reagents
Rat anti-mouse VCAM-1 (clone MVCAM.A), mouse anti-
human VCAM-1 (clone 51-10C9), and rat anti-mouse CD98
(clone H202-141) were from BD PharMingen, San Diego, CA.
Goat anti-mouse IgG1 (catalog #1070-01) and goat anti-rat IgG
(catalog #3050-01) were from Southern Biotech, Birmingham,
AL. The phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204)
(clone D13.14.4E) XP
TM rabbit antibodies (catalog #4370), the
p44/42 MAPK (Erk1/2) (clone 137F5) rabbit antibodies (catalog
#4695), the rabbit anti-phospho-MEK1/2 (Ser217/221) (clone
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antibodies (catalog #9122), the HRP-conjugated goat anti-rabbit
IgG antibody (catalog #7074), the HRP-conjugated horse anti-
mouse IgG, antibody (catalog #7076) and the MEK1/MEK2
inhibitor U0126 (catalog #9903) were from Cell Signaling
Technology, Beverly, MA. Apocynin (catalog #102420250) was
from Acros Organics, Pittsburg, PA. Go ¨-6976 (catalog #EI-269)
was obtained from Biomol, Plymouth Meeting, PA. H2O2 (catalog
#H-1009) was from Sigma. PD98059 (catalog #BML-EI360-
0005) and CinnGEL 2-methylester (catalog #BML-PR114-0001)
were purchased from Enzo Life Sciences International, Inc
(Plymouth Meeting, PA).
Transient transfection
The rat ERK2 wild type (WT) sequence containing plasmid
pcDNA3-HA-ERK2 WT was purchased from Addgen (plasmid
#8974). ERK2 WT sequence was subcloned to pmaxFP-Green-C
vector (catalog #VDF-1011, Lonza) using BamHI and KpnI
restriction sites. The plasmid was mutated at K52R using Agilent
technologies site directed mutagenesis kit (catalog # 200523-5)
using the primer GTTCGAGTTGCTATCAGGAAAATCAGT
CCTTTTGAGC.
The Nucleofector
TM Kit for Human Microvascular Endothelial
Cells - Lung (HMVEC-L) (catalog #VPB-1003, Lonza) was used
for nucleofection of mHEVa cells. The conditions for optimal
transfection efficiency of .70% were as follows: mHEVa cells
were plated and grown to 70–80% confluent in 3 days. Since the
nucleofection reagent is positively charged and the endothelial cell
surface is highly positively charged, the endothelial cells were
briefly trypsin-treated to remove some surface charge and to
suspend the cells. One million of these endothelial cells were
centrifugation at 700 rpm for 10 minutes and all supernatant was
carefully removed. The resulting cell pellets were suspended in
100 ml of the nucleofection reagent plus 4 mg pmaxFP-Green-C
vector or 4 mg of pmaxFP-Green-C vector containing the ERK2
K52R plasmid. Cells were subsequently transferred into nucleo-
fection cuvettes (Lonza). The endothelial cells were nucleofected
by using the S-005 program in the Amaxa Nucleofector II (Lonza).
Pre-warmed 500 ml EGM-MV plus 5% FCS culture media was
immediately added to the transfected cells, which were subse-
quently cultured in the same media at a density to form confluent
monolayers. The endothelial cells formed confluent monolayers in
four hours and were .90% viable. At four hours of culture,
transfection was confirmed by western blot for total ERK1/2 and
flow cytometry for GFP. Transfection efficiency was determined as
a percentage of GFP-positive cells by flow cytometry.
In vitro cell association and migration assays under
laminar flow or static conditions
A parallel plate flow chamber was used to examine leukocyte
migration under conditions of laminar flow at 2 dynes/cm
2,a s
previously described [7,8] or static conditions. Spleen cells were
used as a source of leukocytes contiguous with the blood stream
that could then migrate across endothelial cells. Spleen cell
migration across the mHEV cell lines is stimulated by mHEV cell
constitutive production of the chemokine MCP-1 [14] and is
dependent on adhesion to VCAM-1 and not other known
adhesion molecules [5,60,61]. We have previously reported that,
consistent with the populations isolated from the spleen, after
migration across the mHEV cells, the spleen cells are 65–70% B
cells, 12–15% CD4+ cells, and 5–8% CD8+ cells [6]. For this
migration assay, endothelial cells were grown to confluence on
slides and then the slide was placed in a parallel plate flow
chamber [23]. In vivo, in the absence of inflammation, the rapid
fluid dynamics of the blood result in blood cells located midstream
of the vascular flow [62]. However, during inflammation, there is a
change of fluid dynamics [62,63,64]. With inflammation, vascular
permeability increases yielding fluid flow from the blood into the
tissues which contributes to bringing blood cells into contact with
the endothelium (‘‘margination’’) [62,64]. There is also cell contact
as the blood cells leave the capillaries and enter the small diameter
postcapillary venules [63]. Therefore, spleen cells (3610
6) were
added to the flow chamber (3.5 cm
2) at 2 dynes/cm
2. Next, to
briefly initiate spleen cell contact with the endothelial cells in vitro,
the spleen cells were allowed to settle in the chamber as monitored
by microscopy and then 2 dynes/cm
2 was applied for the 15 min
laminar flow assay. We have observed by microscopy that during
the assay under laminar flow, the spleen cells in contact with the
endothelial cells either roll, roll and detach, or roll, firmly attach,
and migrate. After cell contact, the focus of the studies is on
mechanisms of transendothelial migration under conditions of
laminar flow. For this assay, the coculture was exposed to laminar
flow at 2 dynes/ cm
2 at 37uC for 2 min to examine cell association
or for 15 min to examine cell migration. After the 2 or 15 min at
2 dynes/ cm
2, the cells are washed with PBS supplemented with
0.2 mM CaCl2 and 0.1 mM MgCl2 because cations are required
for cell adhesion. These cells were fixed with 3% paraformalde-
hyde for 1 h. To quantify migrated spleen cells at 15 min, phase
contrast microscopy was used to count migrated cells that are
phase dark [65]. It has been reported that the transendothelial
migration of an individual leukocyte, after it has rolled to a site of
migration, occurs in 2 min [60]. However, transendothelial
migration of leukocytes is asynchronous. In the laminar flow
assay, spleen cell migration is detected by 15 min. The number of
spleen cells that were associated but not migrated (phase light cells)
at 15 min is low because in 15 min, the majority of nonmigrating
cells roll off the monolayer of endothelial cells as determined by
microscopy (data not shown). Therefore, the numbers of spleen
cells associated with the endothelial cells at 2 min of laminar flow
are those cells that mediated cell-cell contact.
Antibody coated-beads
For anti-mouse VCAM-1-coated beads, streptavidin-coated
9.9 mm diameter beads (80 ml) (Bangs Laboratories) were labeled
with 24 mg of biotin-conjugated goat anti-rat Ig in 375 ml of PBS
with gentle rocking for 1 h at 4uC and then washed three times
[5]. These beads were incubated with 16 mg of rat anti-mouse
VCAM-1 or a rat isotype control antibody in 375 ml of PBS with
gentle rocking for 1 h at 4uC and then washed.
Western blotting
Cell lysates were analyzed by 10% SDS-PAGE and transferred
to nitrocellulose membranes by the semi-dry method according to
manufacturers instructions (Bio-Rad). The membranes were
blocked in 5% non-fat dried milk in Tris-buffered saline plus
0.1% Tween 20 (TBS-T) for 1 hour at room temperature and
washed 3 times for 5 minutes in TBS-T. Membranes were
incubated with primary antibodies in TBS-T plus 5% milk
overnight, washed 3 times for 5 minutes in TBS-T, incubated with
anti-rabbit secondary antibodies in TBS-T plus 5% milk for
1 hour, washed 3 times for 10 minutes in TBS-T, and examined
for detection with the enhanced chemiluminescence kit (catalog
#RPN2132, Amersham) and autoradiography. Equal protein
loading was verified by stripping the membrane with Restore
Western Blot Stripping Buffer (Pierce, Rockford, IL) for 15
minutes and then labeling with rabbit anti-total ERK1/2 or
MEK1/2 where indicated. Densitometry was performed using
Image J software (NIH). The data were presented as the fold
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intensity of band for the loading control (total ERK1/2 or total
MEk1/2 where indicated).
Statistics
Data were analyzed by a one way ANOVA followed by Tukey’s
multiple comparisons test (SigmaStat, Jandel Scientific, San Ramon,
CA).
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